Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-07-31

Clinical Trial Update: Topical Ruxolitinib Evaluation in Chronic Hand Eczema [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating topical ruxolitinib for chronic hand eczema has completed, and its results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Topical ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Hand Eczema | Phase 2 | Status: COMPLETED | Results posted: 2025-07-31